OncoSec Medical Inc (ONCSQ)

[guti]

In addition, the 5th Inflammatory & Immunological Biomarkers Conference which will be one of the three conferences taking part at the Biomarker Summit 2016 to be held on March 21.
Dr. Tumeh will be speaking in the plenary session Novel Technologies in Biomarker Development. For more than a year, Dr. Tumeh has been helping PerkinElmer, UCLA and OncoSec on a collaboration to create a Patient-Selection Biomarker in Immunotherapy.

“Dr. Tumeh has demonstrated the potential of applying his highly quantitative approach to assessing the ‘stalled’ CD8+ lymphocytes, which are the key effector cells driving response to anti-PD-1 therapy. This work has the potential to identify responders from non-responders. Dr. Tumeh’s work, combined with PerkinElmer’s technology, may lead to the development of a critical diagnostic tool for identifying non-responders to anti-PD-1 monotherapy". Dr. Pierce.